MONOCLONAL ANTIBODIES
IN CANCER
Engineered to bind a single specific target on cancer cells โ then act on whatever carries it. Four distinct types with genuinely different mechanisms, approvals, and clinical behaviors. Which one you receive matters more than knowing you are on an antibody.
What This Means for Patients
Your immune system makes antibodies naturally โ each one a precision instrument binding to one specific target. Monoclonal antibodies are laboratory-engineered versions of this process, designed to bind a specific marker relevant to a specific cancer. What happens after binding is where the types diverge: some flag cancer cells for immune destruction, some block a growth signal the cancer depends on, some carry a toxic drug directly to the cell, and some pull T-cells into direct contact with the cancer.
Types of Monoclonal Antibodies in Cancer
Four distinct types โ each with different mechanisms, approved cancer targets, and clinical considerations.
Naked Monoclonal Antibodies
Bind to a target and either block a function or flag the cell for immune attack. Trastuzumab for HER2-positive breast and gastric cancers. Rituximab for CD20-positive B-cell lymphomas. Cetuximab for EGFR-expressing colorectal and head and neck cancers.
Antibody-Drug Conjugates (ADCs)
A monoclonal antibody linked to a cytotoxic drug โ delivering the toxin specifically to cancer cells, reducing systemic exposure. T-DXd (trastuzumab deruxtecan) and sacituzumab govitecan are among the most clinically significant recent approvals. ADCs are the fastest-developing area in oncology currently.
Bispecific Antibodies
Engineered to bind two targets simultaneously โ typically connecting a T-cell directly to a cancer cell. Blinatumomab (CD3 + CD19) approved for certain leukemias. The category is expanding into solid tumors.
Checkpoint-Targeting Antibodies
Pembrolizumab, nivolumab, and ipilimumab are technically monoclonal antibodies targeting immune checkpoints. Discussed separately under checkpoint inhibitors because the clinical context is distinct โ same underlying technology.
Key Approved Monoclonal Antibodies
Selected agents with established clinical use across major cancer types.
| Drug | Type | Target | Key Indications |
|---|---|---|---|
| Trastuzumab (Herceptin) | Naked mAb | HER2 | HER2+ breast, gastric/GEJ cancer |
| Rituximab (Rituxan) | Naked mAb | CD20 | B-cell NHL, CLL, follicular lymphoma |
| Cetuximab (Erbitux) | Naked mAb | EGFR | Colorectal, HNSCC (KRAS WT) |
| T-DXd (Enhertu) | ADC | HER2 | HER2+ breast, gastric, NSCLC, CRC |
| Sacituzumab govitecan | ADC | Trop-2 | TNBC, urothelial carcinoma |
| Blinatumomab (Blincyto) | BiTE | CD3 + CD19 | r/r B-cell ALL, Ph- B-ALL |
| Enfortumab vedotin | ADC | Nectin-4 | Advanced urothelial carcinoma |
Who This Is Relevant For
Patients whose tumors express specific protein targets. HER2, EGFR, CD20 โ biomarker testing determines whether the target is present at levels sufficient for the antibody to work. Without the target, the antibody has nothing to bind to. Comprehensive molecular testing at diagnosis makes targeted antibody conversations possible.
Benefits and Limitations
Benefits
- Precision targetingConcentrates treatment at cancer cells expressing the target โ reducing exposure to healthy tissue.
- Different side effect profileTargeted antibodies typically do not cause the hair loss or bone marrow suppression of cytotoxic chemotherapy.
- ADC responses in resistant diseaseT-DXd has shown responses in patients who stopped responding to prior HER2-targeted agents.
Limitations
- Resistance developsCancers can lose or reduce expression of the target over time โ driving need for next-generation agents.
- Biomarker testing requiredHER2, EGFR, CD20 testing are prerequisites. Without a confirmed target, the conversation cannot proceed.
- ADC toxicity profileInterstitial lung disease (with T-DXd) and peripheral neuropathy (with other ADCs) require monitoring.
How It Fits Into Advanced Cancer Treatment
Monoclonal antibodies occupy a space between classical immunotherapy and targeted therapy in the Cancer Immunotherapy field. Many patients receive them as components of combination regimens โ alongside chemotherapy, checkpoint inhibitors, or both. ADCs in particular are reshaping treatment sequencing in breast, lung, and bladder cancer.
Frequently Asked Questions
Monoclonal Antibody Questions
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Has Your Tumor Been Tested for HER2, EGFR, or CD20?
Monoclonal antibody eligibility starts with biomarker testing. Upload your medical reports and our oncology specialists will review your molecular profile and identify which targeted options โ if any โ apply to your diagnosis.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.